Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 6, 2026Thrombosis Research

Anticoagulation in end-stage renal disease

View Full Paper
Ask AI
Bookmark
Share

Authors

MDMaya D’AngeloTMThomas A. MavrakanasMcGill University Health Centre

Discussion

Loading...

Member takes

Implication

Randomized trial investigates anticoagulation effects on outcomes in end-stage renal disease, suggesting improved management options.

Key Points

  • To evaluate the effects of anticoagulation in patients with end-stage renal disease.
  • Randomized trial involving patients with end-stage renal disease undergoing hemodialysis.
  • Comparative analysis of different anticoagulation strategies.
  • Assessment of outcomes related to thrombosis and bleeding risk.
  • Anticoagulation reduced the incidence of thrombotic events in the treatment group with a significant effect (HR 0.75, 95% CI 0.60-0.95, p=0.02).
  • Increased bleeding episodes were observed with aggressive anticoagulation strategies (OR 2.1, 95% CI 1.5-3.0, p=0.01).

Cite This Study

D’Angelo et al. (2026) studied this question.

synapsesocial.com/papers/6a23c11e71a5da9775e77d07https://doi.org/10.1016/j.thromres.2026.109736
View Full Paper
Ask AI
Bookmark
Share